Treace Medical Concepts, Inc. (NASDAQ:TMCI) Given Consensus Rating of “Reduce” by Brokerages

Posted by on May 28th, 2026

Shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI – Get Free Report) have received an average recommendation of “Reduce” from the seven brokerages that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $4.77.

A number of research firms have recently weighed in on TMCI. Wall Street Zen raised shares of Treace Medical Concepts from a “strong sell” rating to a “sell” rating in a research report on Monday, April 27th. Weiss Ratings reissued a “sell (e+)” rating on shares of Treace Medical Concepts in a research report on Monday, April 20th. Finally, Lake Street Capital decreased their price target on shares of Treace Medical Concepts from $7.50 to $7.00 and set a “buy” rating for the company in a research report on Monday, March 2nd.

Read Our Latest Stock Analysis on TMCI

Insider Buying and Selling at Treace Medical Concepts

In related news, CEO John T. Treace purchased 61,750 shares of the firm’s stock in a transaction dated Thursday, May 14th. The stock was acquired at an average price of $2.62 per share, with a total value of $161,785.00. Following the completion of the transaction, the chief executive officer owned 7,158,313 shares of the company’s stock, valued at $18,754,780.06. This represents a 0.87% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have purchased a total of 153,763 shares of company stock worth $375,667 over the last three months. 23.42% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Treace Medical Concepts

Large investors have recently added to or reduced their stakes in the company. Osaic Holdings Inc. lifted its stake in Treace Medical Concepts by 328.3% during the second quarter. Osaic Holdings Inc. now owns 4,793 shares of the company’s stock worth $28,000 after purchasing an additional 3,674 shares during the last quarter. Captrust Financial Advisors bought a new position in Treace Medical Concepts during the second quarter worth $62,000. Graham Capital Management L.P. bought a new position in Treace Medical Concepts during the fourth quarter worth $27,000. Mercer Global Advisors Inc. ADV bought a new position in Treace Medical Concepts during the third quarter worth $87,000. Finally, HighTower Advisors LLC bought a new position in Treace Medical Concepts during the fourth quarter worth $33,000. 84.08% of the stock is currently owned by institutional investors.

Treace Medical Concepts Stock Up 2.5%

TMCI stock opened at $2.90 on Thursday. Treace Medical Concepts has a twelve month low of $1.17 and a twelve month high of $7.78. The company has a current ratio of 3.58, a quick ratio of 2.53 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $188.12 million, a P/E ratio of -2.99 and a beta of 1.10. The firm has a 50 day simple moving average of $1.91 and a 200-day simple moving average of $2.25.

Treace Medical Concepts (NASDAQ:TMCI – Get Free Report) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03. Treace Medical Concepts had a negative net margin of 29.44% and a negative return on equity of 67.04%. The business had revenue of $47.20 million during the quarter, compared to the consensus estimate of $45.96 million. On average, equities research analysts predict that Treace Medical Concepts will post -0.88 earnings per share for the current fiscal year.

About Treace Medical Concepts

(Get Free Report)

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.

Featured Articles

Analyst Recommendations for Treace Medical Concepts (NASDAQ:TMCI)

Receive News & Ratings for Treace Medical Concepts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Treace Medical Concepts and related companies with MarketBeat.com's FREE daily email newsletter.